Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 5, 2007, Pages 601-613

  Strauss, B E ^a,c   Costanzi Strauss, E ^b,c  

^a Lab de Cardiologia Molecular   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MCT   (Brazil)

Author keywords

Adverse event; Clinical trial; Gene therapy; Insertional mutagenesis; Retrovirus; Severe combined immune deficiency

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RETROVIRUS VECTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DRUG SAFETY; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LYMPHOPROLIFERATIVE DISEASE; MOLONEY LEUKEMIA ONCOVIRUS; MUTAGENESIS; NONHUMAN; ONCOGENE; REVIEW; RISK REDUCTION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION; X CHROMOSOME LINKED DISORDER;

EID: 34248174884     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/s0100-879x2006005000085     Document Type: Review

References (58)

1. Gaspar HB, Thrasher AJ. Gene therapy for severe combined immunodeficiencies. Expert Opin Biol Ther 2005; 5: 1175-1182.
2. Srivastava A. Hematopoietic stem cell transduction by recombinant adeno-associated virus vectors: problems and solutions. Hum Gene Ther 2005; 16: 792-798.
3. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187.
4. Cavazzana-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. Nature 2004; 427: 779-781.
5. Schmalstieg FC, Goldman AS. Immune consequences of mutations in the human common gamma-chain gene. Mol Genet Metab 2002; 76: 163-171.
6. Malek TR, Porter BO, He YW. Multiple gamma c-dependent cytokines regulate T-cell development. Immunol Today 1999; 20: 71-76.
7. Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med 1995; 333: 431-440.
8. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000; 343: 1313-1324.
9. Buckley RH, Schiff SE, Schiff RI, Marked L, Williams LW, Roberts JL, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340: 508-516.
10. Haddad E, Landais P, Friedrich W, Gerritsen B, Cavazzana-Calvo M, Morgan G, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998; 91: 3646-3653.
11. Hacein-Bey-Abina S, le Deist F, Carlier F, Bouneaud C, Hue C, de Villartay JP, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193.
12. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
13. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
14. Buckley RH. Gene therapy for SCID - a complication after remarkable progress. Lancet 2002; 360: 1185-1186.
15. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
16. Nam CH, Rabbitts TH. The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. Mol Ther 2006; 13: 15-25.
17. Frederickson RM. Report from the 2nd stem cell clonality and genotoxicity retreat. Mol Ther 2005; 12: 379-383.
18. Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101: 2099-2114.
19. Aberg JA, Williams PL, Liu T, Lederman HM, Hafner R, Torriani FJ, et al. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. J Infect Dis 2003; 187: 1046-1052.
20. Trono D. Virology. Picking the right spot. Science 2003; 300: 1670-1671.
21. Lund AH, Turner G, Trubetskoy A, Verhoeven E, Wientjens E, Hulsman D, et al. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 2002; 32: 160-165.
22. Mikkers H, Berns A. Retroviral insertional mutagenesis: tagging cancer pathways. Adv Cancer Res 2003; 88: 53-99.
23. Challita PM, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci U S A 1994; 91: 2567-2571.
24. Challita PM, Skelton D, el-Khoueiry A, Yu XJ, Weinberg K, Kohn DB. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol 1995; 69: 748-755.
25. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, Von Kalle C, Meyer J, et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
26. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus leukemia. Science 1997; 276: 1719-1724.
27. Schmidt M, Zickler P, Hoffmann G, Haas S, Wissler M, Muessig A, et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood 2002; 100: 2737-2743.
28. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300: 1749-1751.
29. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303: 333.
30. McCormack MP, Rabbits TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004; 350: 913-922.
31. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994; 78: 45-57.
32. Larson RC, Osada H, Larson TA, Lavenir I, Rabbitts TH. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene 1995; 11: 853-862.
33. Larson RC, Lavenir I, Larson TA, Baer R, Warren AJ, Wadman I, et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J 1996; 15: 1021-1027.
34. Foroni L, Boehm T, White L, Forster A, Sherrington P, Liao XB, et al. The rhombotin gene family encode related LIM-domain proteins whose differing expression suggests multiple roles in mouse development. J Mol Biol 1992; 226: 747-761.
35. Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci U S A 1998; 95: 3890-3895.
36. Berns A. Good news for gene therapy. N Engl J Med 2004; 350: 1679-1680.
37. Kustikova OS, Wahlers A, Kuhlcke K, Stahle B, Zander AR, Baum C, et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003; 102: 3934-3937.
38. Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z, et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005; 105: 4235-4246.
39. Kustikova O, Fehse B, Modlich U, Yang M, Dullmann J, Kamino K, et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005; 308: 1171-1174.
40. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
41. Woods NB, Bottero V, Schmidt M, Von Kalle C, Verma IM. Gene therapy: therapeutic gene causing lymphoma. Nature 2006; 440: 1123.
42. Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A 2006; 103: 11730-11735.
43. Kaiser J. Gene therapy. RAC's advice: proceed with caution. Science 2002; 298: 2113-2115.
44. Check E. Second cancer case halts gene-therapy trials. Nature 2003; 421: 305.
45. Check E. Gene therapists hopeful as trials resume with childhood disease. Nature 2004; 429: 587.
46. Friedmann T. Gene therapy's new era: a balance of unequivocal benefit and unequivocal harm. Mol Ther 2003; 8: 5-7.
47. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346-358.
48. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 2006; 13: 1031-1049.
49. Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA, et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 2006; 13: 391-400.
50. Groth AC, Calos MP. Phage integrases: biology and applications. J Mol Biol 2004; 335: 667-678.
51. Ishikawa Y, Tanaka N, Murakami K, Uchiyama T, Kumaki S, Tsuchiya S, et al. Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines. J Gene Med 2006; 8: 646-653.
52. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435: 646-651.
53. Check E. Harmful potential of viral vectors fuels doubts over gene therapy. Nature 2003; 423: 573-574.
54. Themis M, Waddington SN, Schmidt M, Von Kalle C, Wang Y, Al-Allaf F, et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 2005; 12: 763-771.
55. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696.
56. Baum C, Schambach A, Bohne J, Galla M. Retrovirus vectors: toward the plentivirus? Mol Ther 2006; 13: 1050-1063.
57. Strauss BE, Costanzi-Strauss E. pCLPG: a p53-driven retroviral system. Virology 2004; 321: 165-172.
58. Strauss BE, Bajgelman MC, Costanzi-Strauss E. A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition. Cancer Gene Ther 2005; 12: 935-946.